Skip to content

Clinical study of lipoarabinmannan antigen detection based on chemiluminescence in theClinical study of lipoarabinmannan antigen detection based on chemiluminescence in the diagnosis and efficacy evaluation of patients with active tuberculosis diagnosis and efficacy evaluation of patients with active tuberculosis

Clinical study of lipoarabinmannan antigen detection based on chemiluminescence in the diagnosis and efficacy evaluation of patients with active tuberculosis

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108647
Enrollment
Unknown
Registered
2025-09-03
Start date
2024-11-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberculosis

Interventions

Gold Standard:The patient is considered to have tuberculosis based on the final clinical diagnosis or microbiological diagnosis as the gold standard, i.e., a clinical diagnosis of tuberculosis is tube
Index test:Ultra-sensitive Electrochemiluminescence Urine Lipoarabinomannan Assay,Urine LAM

Sponsors

Beijing Tuberculosis and Thoracic Tumor Research Institute
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Inclusion Criteria for Adult Pulmonary Tuberculosis (Excluding Tuberculous Pleurisy) Samples A. Patients suspected of having tuberculosis in the tuberculosis department or infectious diseases department, with clinical symptoms (cough, expectoration for = 2 weeks) and abnormal imaging findings; B. No gender restriction, aged 18-80 years; C. Newly treated hospitalized patients; D. Having clear clinical diagnosis information, including basic information of clinical samples, medical records and other information. (2) Inclusion Criteria for Pediatric Pulmonary Tuberculosis Patient Samples A. Patients suspected of having tuberculosis in the tuberculosis department or infectious diseases department, with clinical symptoms (cough, expectoration for = 2 weeks) and abnormal imaging findings; B. No gender restriction, aged 0-14 years; C. Newly treated hospitalized patients; D. Having clear clinical diagnosis information, including basic information of clinical samples, medical records and other information. (3) Inclusion Criteria for Newly Treated Drug-Susceptible Pulmonary Tuberculosis Patients A. Based on the diagnosis of clinically active tuberculosis; patients diagnosed with active tuberculosis are determined as positive, with no gender restriction; B. Patients with positive GeneXpert (Mycobacterium tuberculosis molecular detection GeneXpert) and rifampicin susceptibility; C. Patients with positive initial sputum culture results and positive urine LAM detection results; D. Newly treated hospitalized patients with pulmonary tuberculosis; E. Having clear clinical diagnosis information, including basic information of clinical samples, medical records and other information.

Exclusion criteria

Exclusion criteria: 1. Positive Sample Exclusion Criteria A. Patients suspected of having tuberculosis without a clear diagnosis; B. Patients from whom a qualified urine sample cannot be collected. 2. Exclusion Criteria for Newly Treated Drug-Susceptible Pulmonary Tuberculosis Patients A. Patients suspected of having tuberculosis with a confirmed diagnosis (Note: This item may require confirmation of clinical logic; typically, "confirmed diagnosis" is an inclusion condition, and it is recommended to verify whether it is a wording error such as "unconfirmed diagnosis"); B. Newly treated tuberculosis patients with drug resistance; C. Patients from whom a qualified urine sample cannot be collected.

Design outcomes

Primary

MeasureTime frame
sensitivity;Specificity;

Countries

China

Contacts

Public ContactPang Yu

Beijing Chest Hospital, Capital Medical University

pangyupound@163.com+86 138 1009 8209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026